ES2171465T3 - Inhibidor de la esterasa de c1 para reducir lesiones de miocardio durante un infarto de miocardio agudo. - Google Patents

Inhibidor de la esterasa de c1 para reducir lesiones de miocardio durante un infarto de miocardio agudo.

Info

Publication number
ES2171465T3
ES2171465T3 ES94929047T ES94929047T ES2171465T3 ES 2171465 T3 ES2171465 T3 ES 2171465T3 ES 94929047 T ES94929047 T ES 94929047T ES 94929047 T ES94929047 T ES 94929047T ES 2171465 T3 ES2171465 T3 ES 2171465T3
Authority
ES
Spain
Prior art keywords
esterase inhibitor
miocard
pct
myocardial infarction
acute myocardial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94929047T
Other languages
English (en)
Inventor
Willem Theodoor Hermens
Cornelis Erik Hack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stichting Sanquin Bloedvoorziening
Original Assignee
Stichting Sanquin Bloedvoorziening
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting Sanquin Bloedvoorziening filed Critical Stichting Sanquin Bloedvoorziening
Application granted granted Critical
Publication of ES2171465T3 publication Critical patent/ES2171465T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrotherapy Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

UN METODO DE TRATAMIENTO TERAPEUTICO O PROFILACTICO DE LA INFARTACION MIOCARDICA AGUDA, QUE CONSISTE EN ADMINISTRAR UN INHIBIDOR DE LA ESTERASA C1 EXOGENO, POR SI SOLO O COMBINADO CON OTROS FARMACOS, A UN PACIENTE CON INFARTACION MIOCARDICA AGUDO O A UN PACIENTE CON RIESGO DE PADECER UN INFARTO DE MIOCARDIO AGUDO. EL TRATAMIENTO INHIBE LA REACCION INFLAMATORIA, Y DE MANERA MAS ESPECIFICA LA ACTIVACION DEL SISTEMA COMPLEMENTO, QUE TIENE LUGAR DURANTE UNA INFARTACION MIOCARDICA AGUDO. EL INHIBIDOR DE LA ESTERASA C1 PUEDE INCLUIR UN INHIBIDOR DE LA ESTERASA C1 PURIFICADO A PARTIR DE UN PLASMA O DE OTROS MATERIALES BIOLOGICOS, O UN INHIBIDOR DE LA ESTERASA C1 RECOMBINANTE, O ESTRUCTURAS RECOMBINANTES DE OTROS INHIBIDORES QUE POSEEN UNA ESPECIFICIDAD SIMILAR A LA DEL INHIBIDOR DE LA ESTERASA C1.
ES94929047T 1993-09-01 1994-08-31 Inhibidor de la esterasa de c1 para reducir lesiones de miocardio durante un infarto de miocardio agudo. Expired - Lifetime ES2171465T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP93202572 1993-09-01

Publications (1)

Publication Number Publication Date
ES2171465T3 true ES2171465T3 (es) 2002-09-16

Family

ID=8214075

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94929047T Expired - Lifetime ES2171465T3 (es) 1993-09-01 1994-08-31 Inhibidor de la esterasa de c1 para reducir lesiones de miocardio durante un infarto de miocardio agudo.

Country Status (10)

Country Link
US (1) US6090777A (es)
EP (1) EP0716611B1 (es)
JP (2) JP4077030B2 (es)
AT (1) ATE212859T1 (es)
AU (1) AU678064B2 (es)
DE (1) DE69429816T2 (es)
DK (1) DK0716611T3 (es)
ES (1) ES2171465T3 (es)
PT (1) PT716611E (es)
WO (1) WO1995006479A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19829014A1 (de) * 1998-06-30 2000-01-05 Centeon Pharma Gmbh Modifizierter C1-Esterase-Inhibitor zur Blockierung der Infektiosität von HIV
US7008645B2 (en) * 1998-07-14 2006-03-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of inhibiting restenosis using bisphosphonates
CA2426115A1 (en) * 2003-04-18 2004-10-18 Victor Gurewich Methods, devices, and compositions for lysis of occlusive blood clots while sparing wound sealing clots
US10517883B2 (en) * 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
US20060051407A1 (en) * 2003-06-27 2006-03-09 Yoram Richter Method of treating ischemia-reperfusion injury
US20070196367A1 (en) * 2006-02-22 2007-08-23 Valentin Dinu Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
US20090010916A1 (en) * 2006-06-22 2009-01-08 Victor Gurewich C-1 Inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis
US8703136B2 (en) 2006-10-10 2014-04-22 Regenesance B.V. Complement inhibition for improved nerve regeneration
CA2889170C (en) 2012-10-25 2021-09-07 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
RS63212B1 (sr) 2012-11-02 2022-06-30 Bioverativ Usa Inc Antikomplementna c1s antitela i njihove primene
ES2609070T3 (es) * 2013-02-28 2017-04-18 Csl Behring Gmbh Agente terapéutico para el embolismo de líquido amniótico
KR102403299B1 (ko) * 2013-03-08 2022-06-03 체에스엘 베링 게엠베하 원격 허혈-재관류 손상의 치료 및 예방
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
EP2968434B1 (en) * 2013-03-15 2017-06-28 Shire Viropharma Incorporated C1-inh compositions for use in the prevention and treatment of hereditary angioedema (hae).
KR20160026905A (ko) * 2013-06-28 2016-03-09 체에스엘 베링 게엠베하 인자 ｘｉｉ 억제제 및 ｃ1-억제제를 이용한 병용 치료요법
EP4212175A1 (en) 2015-04-06 2023-07-19 Bioverativ USA Inc. Humanized anti-c1s antibodies and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3228502A1 (de) * 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung des c1-inaktivators und seine verwendung
FR2601034B1 (fr) * 1986-07-03 1989-11-17 Pasteur Institut Inhibiteur de l'activite de la c1-esterase plasmatique (c1-inhibiteur) et d'autres enzymes proteolytiques du groupe des proteases a serine, son procede de preparation, acides nucleiques codant pour cet inhibiteur, methodes de detection d'affections correlees aux defauts dudit inhibiteur a l'aide d'anticorps ou de sondes nucleotidiques et medicaments contenant ledit inhibiteur de synthese
EP0497833A1 (en) * 1989-10-27 1992-08-12 Stichting Centraal Laboratorium van de Bloedtransfusiedienst van het Nederlandse Rode Kruis C1 inhibitor muteins and uses thereof
WO1992022320A1 (en) * 1991-06-14 1992-12-23 Genentech, Inc. C1 inhibitor variants and treating inflammatory response with c1 inhibitor

Also Published As

Publication number Publication date
DK0716611T3 (da) 2002-05-21
JP2008056705A (ja) 2008-03-13
AU7823994A (en) 1995-03-22
WO1995006479A1 (en) 1995-03-09
US6090777A (en) 2000-07-18
ATE212859T1 (de) 2002-02-15
AU678064B2 (en) 1997-05-15
PT716611E (pt) 2002-06-28
EP0716611B1 (en) 2002-02-06
DE69429816T2 (de) 2002-09-19
EP0716611A1 (en) 1996-06-19
DE69429816D1 (de) 2002-03-21
JPH09501946A (ja) 1997-02-25
JP4077030B2 (ja) 2008-04-16

Similar Documents

Publication Publication Date Title
ES2171465T3 (es) Inhibidor de la esterasa de c1 para reducir lesiones de miocardio durante un infarto de miocardio agudo.
MX9700237A (es) Combinaciones inhibidoras de proteasa retroviral.
NO307027B1 (no) Anvendelse av riluzol ved behandling av neurologiske lesjoner relatert til traumatiske skader
MY129293A (en) The use of mmp-13 selective inhibitors for the treatment of osteoarthristis and other mmp-mediated disorders
EP1007556A4 (en) TROPONIN SUB-UNITS AND FRAGMENTS FOR USE AS INHIBITORS OF ANGIOGENESIS
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
BR9713186A (pt) Inibidores de metaloprotease 1,3-diheterocìclicos
HU9204029D0 (en) Proteolytic enzym inhibitors
DE69410254T2 (de) Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
UA41355C2 (uk) Засіб для лікування нейро-сніду
IL110943A (en) Compositions comprising an inhibitor of cholesterol synthesis for the treatment of skin disorders
DE69333639D1 (en) Trypsininhibitoren
TW268937B (es)
ATE252389T1 (de) Ein arzneimittel zur behandlung von fettleibigkeit und verbesserung des lipidmetabolismus
DK0876158T3 (da) Ny medicinsk anvendelse af en ACE-inhibitor til behandling af mavesurhedssymptomer
CZ157795A3 (en) Pharmaceutical preparations for treating prostatitis
CA2170739A1 (en) Method to reduce myocardial injury during acute myocardial infarction
AU4390597A (en) Combination therapy for treatment of arthritic diseases
AU5857899A (en) Use of tgf-beta inhibitors for treating cerebral disorders
ES2058025A1 (es) Aplicacion del acido fitico y/o sus fitatos en los estados patologicos y prepatologicos derivados de la litiasis renal oxalocalcica idiopatica.
GEP19991605B (en) Inhibitor, Its Obtaining and Use

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 716611

Country of ref document: ES